Chen Jie, founding partner of Suzhou-based BioVenture, invests in early-stage life sciences companies—primarily seed. See sector focus and contact routes.
Chen Jie, founding partner of Suzhou-based BioVenture, invests in early-stage life sciences companies—primarily seed and Series A rounds—in biotechnology, drug discovery, medical devices, and healthcare services, with typical check sizes of RMB 30–50 million. His portfolio includes notable companies such as Ark Biosciences (which he led in a Series A+ extension), Kintor Pharmaceutical, PegBio, BrightGene, and Ascentage Pharma. Jie’s distinctive thesis emphasizes targeting high-growth markets in cancer, diabetes, and cardiac diseases while prioritizing ventures with strong technology IP and high entry barriers.
This profile is part of the StartupFundraising investor database: focus, portfolio history, disclosed location and contact routes, refreshed as new filings and rounds are ingested. Founders use it to check fit before reaching out and to find investors in Suzhou.
Investors like Chen Jie · Full investor directory · Investor access · Company funding database